Literature DB >> 35258698

Association of androgen excess and bone mineral density in women with classical congenital adrenal hyperplasia with 21-hydroxylase deficiency.

Dong Ho Lee1,2, Sung Hye Kong2,3, Han Na Jang1,2, Chang Ho Ahn2,3, Seung Gyun Lim1,2, Young Ah Lee4, Sang Wan Kim2,5, Jung Hee Kim6,7.   

Abstract

The relationship between androgen excess and bone health in patients with congenital adrenal hyperplasia (CAH) with 21-hydroxylase (21-OH) deficiency is not fully understood. This study demonstrated positive correlations between androgen hormones and bone mineral density (BMD) in CAH women with 21-OH deficiency.
PURPOSE: This study aims to assess BMD and its association with androgen excess in women with CAH.
METHODS: We enrolled 92 women with CAH with 21-OH deficiency and retrospectively reviewed their clinical features, hormone concentrations, body composition, glucocorticoid (GC) dose, and BMD.
RESULTS: BMD was not different according to the subtypes of CAH. BMD at the lumbar spine was lower in women with CAH with regular menstruation than those with irregular menstruation (1.081 vs. 1.165 g/cm2, P < 0.05). BMD was lower in women with CAH with 17-hydroxyprogesterone (17-OHP) < 10 ng/mL than in those with ≥ 10 ng/mL (lumbar spine, 1.019 vs. 1.150 g/cm2; femur neck, 0.806 vs. 0.899 g/cm2; total hip, 0.795 vs. 0.943 g/cm2; all P < 0.05). After adjusting for age and BMI in correlation analyses, testosterone concentrations were positively correlated with lumbar spine, femur neck, and total hip BMD (r = 0.46, r = 0.38, and r = 0.35, respectively; all P < 0.05), while 17-OHP was positively correlated with lumbar spine BMD (r = 0.38, P < 0.01). In subgroup analysis, 17-OHP was positively correlated with BMD (lumbar spine, r = 0.22; femur neck, r = 0.22; total hip, r = 0.24; all P < 0.05) only in the group with a total cumulative dose of GC ≥ 156.0 g/m2.
CONCLUSION: Androgen excess may have a protective effect on BMD in women with classic CAH and high cumulative doses of GC.
© 2022. International Osteoporosis Foundation and National Osteoporosis Foundation.

Entities:  

Keywords:  21-Hydroxylase; Adrenal hyperplasia, Congenital; Androgen; Bone mineral density; GCs

Mesh:

Substances:

Year:  2022        PMID: 35258698     DOI: 10.1007/s11657-022-01090-0

Source DB:  PubMed          Journal:  Arch Osteoporos            Impact factor:   2.617


  21 in total

Review 1.  Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment.

Authors:  Pojchong Chotiyarnwong; Eugene V McCloskey
Journal:  Nat Rev Endocrinol       Date:  2020-04-14       Impact factor: 43.330

2.  Influence of hormonal control on LH pulsatility and secretion in women with classical congenital adrenal hyperplasia.

Authors:  Anne Bachelot; Zeina Chakhtoura; Geneviève Plu-Bureau; Mathieu Coudert; Christiane Coussieu; Yasmina Badachi; Jérome Dulon; Beny Charbit; Philippe Touraine
Journal:  Eur J Endocrinol       Date:  2012-08-14       Impact factor: 6.664

3.  Clinical and hormonal profiles correlate with molecular characteristics in patients with 11β-hydroxylase deficiency.

Authors:  Melek Yildiz; Emregul Isik; Zehra Yavas Abali; Mehmet Keskin; Mehmet Nuri Ozbek; Firdevs Bas; Seyit Ahmet Ucakturk; Muammer Buyukinan; Hasan Onal; Cengiz Kara; Karl-Heinz Storbeck; Feyza Darendeliler; Atilla Cayir; Edip Unal; Ahmet Anik; Huseyin Demirbilek; Tugba Cetin; Fatma Dursun; Gonul Catli; Serap Turan; Henrik Falhammar; Tugba Baris; Ali Yaman; Goncagul Haklar; Abdullah Bereket; Tulay Guran
Journal:  J Clin Endocrinol Metab       Date:  2021-04-08       Impact factor: 5.958

4.  Bone mass and body composition of adult women with congenital virilizing 21-hydroxylase deficiency after glucocorticoid treatment since infancy.

Authors:  K Hagenfeldt; E Martin Ritzén; H Ringertz; J Helleday; K Carlström
Journal:  Eur J Endocrinol       Date:  2000-11       Impact factor: 6.664

5.  Bone mineral density is not significantly reduced in adult patients on low-dose glucocorticoid replacement therapy.

Authors:  K R Koetz; M Ventz; S Diederich; M Quinkler
Journal:  J Clin Endocrinol Metab       Date:  2011-10-12       Impact factor: 5.958

6.  Cardiovascular and Metabolic Outcomes in Congenital Adrenal Hyperplasia: A Systematic Review and Meta-Analysis.

Authors:  Shrikant Tamhane; Rene Rodriguez-Gutierrez; Anoop Mohamed Iqbal; Larry J Prokop; Irina Bancos; Phyllis W Speiser; Mohammad Hassan Murad
Journal:  J Clin Endocrinol Metab       Date:  2018-11-01       Impact factor: 5.958

7.  Fractures and bone mineral density in adult women with 21-hydroxylase deficiency.

Authors:  Henrik Falhammar; Helena Filipsson; Gundela Holmdahl; Per-Olof Janson; Agneta Nordenskjöld; Kerstin Hagenfeldt; Marja Thorén
Journal:  J Clin Endocrinol Metab       Date:  2007-09-18       Impact factor: 5.958

Review 8.  Effects of adrenal steroids on the bone metabolism of children with congenital adrenal hyperplasia.

Authors:  Karen Lin-Su; Maria I New
Journal:  Ann N Y Acad Sci       Date:  2007-11       Impact factor: 5.691

9.  Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline.

Authors:  Phyllis W Speiser; Wiebke Arlt; Richard J Auchus; Laurence S Baskin; Gerard S Conway; Deborah P Merke; Heino F L Meyer-Bahlburg; Walter L Miller; M Hassan Murad; Sharon E Oberfield; Perrin C White
Journal:  J Clin Endocrinol Metab       Date:  2018-11-01       Impact factor: 5.958

10.  Glucocorticoid Regimens in the Treatment of Congenital Adrenal Hyperplasia: A Systematic Review and Meta-Analysis.

Authors:  Emma Whittle; Henrik Falhammar
Journal:  J Endocr Soc       Date:  2019-04-18
View more
  2 in total

1.  Association between Serum Total Testosterone Level and Bone Mineral Density in Middle-Aged Postmenopausal Women.

Authors:  JinXiao Yang; Guofei Kong; Xiaocong Yao; Zhongxin Zhu
Journal:  Int J Endocrinol       Date:  2022-08-17       Impact factor: 2.803

Review 2.  Long-Term Outcomes of Congenital Adrenal Hyperplasia.

Authors:  Anna Nordenström; Svetlana Lajic; Henrik Falhammar
Journal:  Endocrinol Metab (Seoul)       Date:  2022-07-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.